MiNK Therapeutics to Participate in Evercore ISI HealthCONx Conference
MiNK Therapeutics, a biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on December 1st at 4:45 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiNK Therapeutics, a biopharmaceutical company, announced that Dr. Jennifer Buell, President and CEO, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on December 1st at 4:45 PM ET. The event will be accessible live via a provided link, with a replay available on the MiNK website afterward. Recently, MiNK presented new data from five presentations at the Society for Immunotherapy of Cancer Annual Meeting on November 10th, showcasing their innovative iNKT cell therapies aimed at treating cancer and immune-mediated diseases.
Details
News Market Reaction – INKT
The recorded move for INKT in the trading session of this news was -5.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference on Thursday December 1st, at 4:45 PM ET.
Access to the live fireside chat is available at https://wsw.com/webcast/evercore29/inkt/2382660. A replay will be available after the call on the Events and Presentations page of the MiNK website at https://investor.minktherapeutics.com/events-and-presentations.
MiNK recently presented new data from five presentations at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 10th. These presentations are available on the MiNK website at https://minktherapeutics.com/publications/.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, visit https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.
Contact
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.